Broadcast Date: March 23, 2021
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

A large proportion of initially promising biotherapeutic candidates never make it to commercialization. This can be due to issues with efficacy, safety, or manufacturability. It can also be due to problems in cell lines or process development for the manufacturing process. Therefore, it is critical to evaluate potential liabilities as early as possible during molecule design and utilize lead selection phases to increase the chances of identifying a successful candidate significantly. It is also essential that the best approaches and tools are selected to maximize success when moving the selected candidate through development.

In this GEN webinar, we will introduce strategies and tools to increase the chance of success through both of these stages. Firstly, initial strategies to optimize the amino acid sequence of the molecule will be discussed and techniques to maximize product safety and quality. Secondly, one tool—GS piggyBac®—which can help improve expression levels, especially for more complex, next-generation biologics, will be discussed.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Alison Porter
Alison Porter, PhD
Head of Expression System Sciences
Lonza
Yvette Stallwood, PhD
Yvette Stallwood, PhD
Head of Applied Protein Services
Lonza

 

The post Right First Time: Successfully Progressing Biotherapeutics from Discovery to the Clinic appeared first on GEN – Genetic Engineering and Biotechnology News.

Source